ArticleParasites & vectors2025
Does fluralaner (Exzolt
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vertical transmission, infection dynamics and risk factors for the occurrence of tick fever agents in beef cattle from a tropical region.Tropical animal health and production · 2026Article
- Overcoming doramectin failure: field efficacy of pour-on 5% fluralaner and an experimental 1% oral formulation for the prevention of Cochliomyia hominivorax-associated umbilical myiasis in newborn calves.Parasites & vectors · 2026Article
- Susceptibility of Rhipicephalus microplus to fluralaner: assessment before and after implementation of a strategic control protocol in taurine cattle in a tropical region.Parasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the impact of fluralaner on herd enzootic stability regarding tick fever pathogens (TFPs). This study aimed to assess whether implementing strategic control of Rhipicephalus microplus using fluralaner could influence the enzootic stability of beef herds regarding TFPs on a farm where this compound had never been previously used.
methodsOne hundred Bos taurus indicus calves were divided into two groups of 50 animals each. One group underwent strategic tick control with pour-on fluralaner at 2.5 mg/kg (FLU), while the control group received a pour-on combination of fipronil 1.25 mg/kg + fluazuron 2.5 mg/kg (FIFLUA), a protocol used on the farm for 12 years. Calves were monitored from 25 to 241 days of age (weaning). During this period, in addition to acaricide treatments, tick counts and TFP diagnosis via indirect enzyme-linked immunosorbent assay (iELISA), quantitative polymerase chain reaction (qPCR), and blood smears were conducted in both groups.
resultsFIFLUA animals received four acaricide treatments at 25, 60, 135, and 188 days of age, with intervals of 35, 75, and 53 days. FLU animals received three acaricide treatments, at 25, 135, and 188 days of age, with intervals of 110 and 53 days. The average tick count in the FLU group was significantly lower than in the FIFLUA group at 60 days (Kruskal-Wallis, H = 97.85, df = 1, P < 0.0001) and 241 days (H = 18.12, df = 1, P < 0.0001). Anaplasma marginale bacteremia was lower in the FLU group at 60 days (H = 3.98, df = 1, P = 0.0459). Serologically, enzootic stability for Babesia bovis was achieved at 135 and 188 days in the FLU and FIFLUA groups, respectively. For B. bigemina, over 75% of calves in both groups showed antibodies at 60 and 188 days, respectively. For A. marginale, enzootic stability was reached at 188 days (FLU) and 241 days (FIFLUA).
conclusionsStrategic tick control with fluralaner did not compromise the development of enzootic stability to B. bovis, B. bigemina, and A. marginale. Over 75% of FLU-treated calves showed seroconversion at 133, 60, and 188 days, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.